EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit /Hyperactivity Disorder

Shen Cheng iD, Mahmoud Al-Kofahi iD, J Steven Leeder iD, Jacob T Brown iD

Clinical Pharmacology & Therapeutics · 2024-05 · 115 (5) · 1033-1043

DOI: 10.1002/cpt.3155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 08.01.2024. Verfasst von Shen Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Propylamines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atomoxetine (ATX) is a non‐stimulant used to treat attention‐deficit/hyperactivity disorder (ADHD) and systemic exposure is highly variable due to polymorphic cytochrome P450 2D6 (CYP2D6) activity. The objective of this study was to characterize the time course of ATX and metabolites (4‐hydroxyatomoxetine (4‐OH); N ‐desmethylatomoxetine (NDA); and 2‐carboxymethylatomoxetine (2‐COOH)) exposure following oral ATX dosing in children with ADHD to support individualized dosing. A nonlinear mixed‐effect modeling approach was used to analyze ATX, 4‐OH, and NDA plasma and urine, and 2‐COOH urine profiles obtained over 24–72 hours from children with ADHD ( n = 23) following a single oral ATX dose. Demographics and CYP2D6 activity score (AS) were evaluated as covariates. Simulations were performed to explore the ATX dosing in subjects with various CYP2D6 AS. A simultaneous pharmacokinetic modeling approach was used in which a model for ATX, 4‐OH, and NDA in plasma and urine, and 2‐COOH in urine was developed. Plasma ATX, 4‐OH, and NDA were modeled using two‐compartment models with first‐order elimination. CYP2D6 AS was a significant determinant of ATX apparent oral clearance (CL/F), fraction metabolized to 4‐OH, and systemic exposure of NDA. CL/F of ATX varied almost 7‐fold across the CYP2D6 AS groups: AS 2: 20.02 L/hour; AS 1: 19.00 L/hour; AS 0.5: 7.47 L/hour; and AS 0: 3.10 L/hour. The developed model closely captures observed ATX, 4‐OH, and NDA plasma and urine, and 2‐COOH urine profiles. Application of the model shows the potential for AS‐based dosing recommendations for improved individualized dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityPropylaminesChildAdolescentHumansAtomoxetine HydrochlorideCytochrome P-450 CYP2D6Phenyl EthersAdrenergic Uptake Inhibitors

Substanzen

Atomoxetine HydrochlorideCytochrome P-450 CYP2D6N-desmethylatomoxetinePhenyl EthersAdrenergic Uptake InhibitorsPropylamines

Autor:innen und Institutionen

  • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City and University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, Minnesota, USA.

ORCID-Profile: Shen Cheng, Mahmoud Al-Kofahi, J Steven Leeder, Jacob T Brown

Förderung

  • NICHD NIH HHS

Zitieren

APA

Cheng, S., Al-Kofahi, M., Leeder, J. S., & Brown, J. T. (2024). Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit /Hyperactivity Disorder. Clinical Pharmacology & Therapeutics, 115(5), 1033-1043. https://doi.org/10.1002/cpt.3155

Vancouver

Cheng S, Al-Kofahi M, Leeder JS, Brown JT. Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit /Hyperactivity Disorder. Clinical Pharmacology & Therapeutics. 2024;115(5):1033-1043. doi:10.1002/cpt.3155

BibTeX
@article{Cheng2024,
  author = {Cheng, Shen and Al-Kofahi, Mahmoud and Leeder, J Steven and Brown, Jacob T},
  title = {Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit /Hyperactivity Disorder},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {115},
  number = {5},
  pages = {1033--1043},
  doi = {10.1002/cpt.3155}
}
Kostenlos starten →